BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CDEX Inc. (CEXI.OB) ID2 Product Line Gains CE Certifications, Begins Distribution in European Union Countries


6/8/2011 8:49:15 AM

TUCSON, AZ--(Marketwire - June 08, 2011) -

CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced today its ID2™ Product line has successfully passed independent testing to verify conformance to the protection requirements of the European Economic Area (EEA) gaining full CE certification. The CE approval means that the entire European market is now open for the company to commercially distribute the ID2 Meth Scanner and Pocket ID2 Illicit Drug Scanner. The company will begin accelerating marketing efforts with its international distribution partners.

The CE Marking Label and the CE Declaration of Conformity are essential for product import and distribution into the European Union (EU) in compliance with all EU Regulations.

"We are very pleased to gain full CE certification allowing our current distribution partners to begin marketing our ID2 products in Europe. Strong demand exists for our innovative technology which is designed for use in law enforcement, correctional facilities and other applications where definitive and immediate results are crucial. Our ID2 meth scanner and ID2 Pocket scanner tests results are instantaneous, with the Pocket ID2 being completely non-destructive, and the ID2 meth scanner requiring a simple 'mining' process for sample gathering. Both products test for the presence of methamphetamine without the user having to touch the scanned surfaces, thus minimizing exposure to personnel and preserving the integrity of the sample substance for future analysis," stated Jeff Brumfield, chairman and chief executive officer of CDEX. "Now we can provide a safe and effective solution to European agencies to detect methamphetamines and soon other illicit drugs such as cocaine. We have received strong interest from our international distributors to gain CE approval for the ID2 product line and expect to begin shipping orders over the next 60 days."

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.

Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.


Company contact:
Jeff Brumfield
CDEX Inc.
(520) 745-5172
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

CDEX Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES